v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues    
Revenues $ 67,864 $ 109,306
Cost of revenues 8,218 24,737
Cost of revenues - related party 30,645 22,505
Gross profit 29,001 62,064
Operating expenses    
General and administrative expenses 1,054,122 1,542,444
Salary and benefits 346,860 349,783
Advertising and marketing 94,073 281,732
Investor relations 12,451 1,419,000
Stock based compensation 1,647,821 1,045,479
Total operating expenses 3,155,327 4,638,438
Loss from operations (3,126,326) (4,576,374)
Other (income) expense    
Interest expense (13,700)
Interest expense - amortization of intangible assets 276,815 276,815
Total other expense 276,815 263,115
Loss before income taxes (3,403,141) (4,839,489)
Income taxes
Net loss (3,403,141) (4,839,489)
Net income (loss) attributed to non-controlling interest 9 (98)
Net loss attributed to Mangoceuticals, Inc. $ (3,403,150) $ (4,839,391)
Basic and diluted loss per share    
Basic loss per share $ (0.22) $ (1.12)
Diluted loss per share $ (0.22) $ (1.12)
Basic 16,481,607 4,593,062
Diluted 16,481,607 4,593,062
Preferred stock dividend requirements $ 294,000 $ 294,000
Net loss attributed to Mangoceuticals, Inc. common stockholders (3,697,150) (5,133,391)
Net loss (3,403,141) (4,839,489)
Other comprehensive income (loss)    
Foreign currency translation adjustments (3,193) 7,624
Comprehensive loss (3,406,334) (4,831,865)
Less comprehensive loss attributed to non-controlling interest (1,533) (98)
Comprehensive loss attributable to Mangoceuticals, Inc. stockholders $ (3,404,801) $ (4,831,767)